drugset / Trial / NCT06949267
A Study of iMSC for the Prevention of Acute Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
RandomizedParallel-groupOpen-labelPrevention
Summary
An open-label, randomized, controlled clinical trial to explore the efficacy and safety of iMSC in preventing the development of acute graft-versus-host disease of degree III-IV in patients after allogeneic hematopoietic stem cell transplantation.
Timeline
- Start
- 2025-06-01
- Primary completion
- 2026-09-30
- Completion
- 2028-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Human Induced Pluripotent Stem Cell-derived Mesenchymal Stromal Cells | Cell therapy | 1e+06 cells/kg | Other |
| Background | Anti-human T-lymphocyte Globulin | Unknown | — | — |
| Background | Cyclosporine | Peptide | — | — |
| Background | Methotrexate | Small molecule | — | — |
| Background | Mycophenolate Mofetil | Small molecule | — | — |
| Background | Tacrolimus | Small molecule | — | — |